Gout drug shows benefit post-MI
But there are too many unanswered questions to use it in practice yet, says expert
Daily low-dose colchicine following treatment for acute MI lowers the risk of subsequent cardiovascular events, results of a large study show.
Nearly 2400 patients randomised to a 0.5mg daily dose of the drug for almost two years were 23% less likely to have any of a composite of cardiovascular events than those taking placebo, found the Canadian-led international trial.
All participants had had an MI in the previous 30 days.
Almost all (98-99%) took aspirin, another antiplatelet drug and a statin throughout the trial, and 93% had undergone percutaneous coronary intervention.
